Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Schmalz

Internal Medicine Bloomington, IN Medical Doctor

NPI 1336255900 CMS profile 14953

3209 W Fullerton Pike, Suite E, Bloomington, IN 47403

Open in the dashboard

General payments

$36,939

1,201 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Schmalz of Bloomington, IN is reported in the CMS Open Payments database as having received $36,939 across 1,201 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21 1
2023 General $59 4
2022 General $3,613 246
2021 General $4,259 318
2020 General $9,593 269
2019 General $19,393 363

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Schmalz
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to William Schmalz were reported at $21. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year William Schmalz Internal Medicine median Middle half National median
2019 $19,393 $159 $48–$570 $163
2020 $9,593 $119 $33–$402 $114
2021 $4,259 $135 $37–$521 $132
2022 $3,613 $141 $42–$496 $149
2023 $59 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $21 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amarin Pharma Inc. $17,180 43 payments
  2. AbbVie, Inc. $5,409 119 payments
  3. Amgen Inc. $2,134 149 payments
  4. AstraZeneca Pharmaceuticals LP $1,469 63 payments
  5. Novartis Pharmaceuticals Corporation $1,083 88 payments
  6. GlaxoSmithKline, LLC. $1,083 94 payments
  7. Lilly USA, LLC $633 59 payments
  8. Novo Nordisk Inc $614 49 payments
  9. Allergan Inc. $572 65 payments
  10. UCB, Inc. $558 47 payments
  11. Other $6,202 425 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,790 8 payments
  2. Food and Beverage $16,648 1,170 payments
  3. Travel and Lodging $2,289 14 payments
  4. Education $212 9 payments
Products named General payments · program years 2019–2025
  1. Vascepa Hypertriglyceridemia $11,254 25 payments
  2. Vascepa Cardiovascular $5,926 18 payments
  3. Otezla $911 59 payments
  4. Repatha $837 51 payments
  5. ENTRESTO $764 69 payments
  6. FARXIGA $628 33 payments
  7. TRELEGY ELLIPTA $609 55 payments
  8. Prolia $595 49 payments
  9. Ozempic $524 39 payments
  10. AIMOVIG $516 36 payments
  11. Other $15,247 1,149 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

62

Median for Internal Medicine: 777

Drug cost

$5,172

Median for Internal Medicine: $73,373

Branded share of claims

19.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tradjenta Linagliptin Brand 12 $3,623
Mirtazapine Generic 13 $650
Amiodarone Hcl Generic 12 $394
Sertraline Hcl Generic 12 $258
Atorvastatin Calcium Generic 13 $247

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

1,201 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record